相关实验视频
Updated: Jan 9, 2026
05:25
Author Spotlight: Enhancing Coronary Artery Revascularization
Published on: September 15, 2023
1.2K
统计剂对隔离冠状动脉旁路移植中出血的影响 统计剂在CABG中对隔离冠状动脉旁路移植的影响
Mustafa Karaarslan1, Osman Fehmi Beyazal1, Nihan Kayalar1
1Department of Cardiovascular Surgery, Basaksehir Cam and Sakura City Hospital, Basaksehir G-434 Street No: 2L, Istanbul 34480, Turkey.
Journal of clinical medicine
|December 11, 2025
概括
在冠状动脉旁路移植 (CABG) 患者手术前使用他类药物并没有增加术后出血. 然而,他类药物显著降低了手术后心房动 (POAF) 的发生率.
科学领域:
- 心脏病学 心脏病学
- 心脏外科手术 心脏外科手术
- 药理学 药理学是指药理学的学科.
背景情况:
- 冠状动脉旁路移植 (CABG) 是一种常见的心脏手术.
- 术前他类药物治疗在缓解术后并发症中的作用正在调查中.
研究的目的:
- 评估术前他类药物对接受单独CABG的患者术后出血和相关并发症的影响.
- 评估术前使用他类药物与术后心房动 (POAF) 的发生之间的关联.
主要方法:
- 一项队列研究,涉及627名患者,在2023年至2025年期间接受隔离CABG.
- 患者被分为两组:手术前使用他类药物的患者 (n=241) 和非使用者 (n=386).
- 术前,术后和术后结果的比较,包括出血,血液制品的使用和POAF.
主要成果:
- 在他类药物使用者和非使用者之间,没有观察到手术内参数,血液制品使用或术后出血的显著差异.
- 在接受术前他类药物的患者中,术后心房 (POAF) 显著降低 (8.7%与19.2%,p < 0.001).
- 在他类药物使用和POAF (OR = 0.418,p = 0.001) 之间发现了显著的负相关性.
结论:
- 术前的他类药物治疗不会增加术后出血或血液制品的需求在孤立的CABG患者.
- 在这个患者队伍中,术前使用他类药物显示出对术后心房动 (POAF) 的保护作用.
相关概念视频
01:27Coronary Artery Disease V: Interprofessional Care
203
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
203
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
01:28Acute Coronary Syndrome IV: Interprofessional Care
197
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
197
01:26Atherosclerosis III: Management
293
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
293
01:26Angina IV: Management
215
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
215